- Accesswire•23 days ago
NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Prana Biotechnology and Xenetic Biosciences both saw their company's stock prices soar on news of a broader, more global product distribution. Prana is continuing ...
- Business Wire•6 months ago
Prana Biotechnology Ltd is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association Annual Meeting in Baltimore, United States.
- Business Wire•9 months ago
Professor Rudolph Tanzi, Founding Scientist and Chief Scientific Advisor for Prana Biotechnology, presented results obtained from testing PBT2, Prana’s lead candidate for Huntington and Alzheimer’s diseases, at the Alzheimer’s Association International Conference in Toronto, Canada on July 26, 2016.
PRAN : Summary for Prana Biotechnology Ltd - Ameri - Yahoo Finance
Prana Biotechnology Limited (PRAN)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Ask||4.60 x 200|
|Day's Range||2.75 - 2.95|
|52 Week Range||1.52 - 6.69|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.07|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|